capecitabine + oxaliplatin + vandetanib

This is a combination regimen consisting of three drugs: - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), a cytotoxic antimetabolite that inhibits DNA synthesis by interfering with thymidylate synthase. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death. - **Vandetanib** is an oral small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases. It blocks angiogenesis and tumor cell proliferation. This combination has been studied in phase I clinical trials for the first-line treatment of metastatic colorectal cancer. The regimen was generally well tolerated at certain doses, but the addition of bevacizumab to this combination increased toxicity[1][2][3]. Vandetanib's mechanism provides targeted therapy against tumor angiogenesis and growth signaling pathways.